[1] Vartivarian SE,Anaissie EJ,Bodey GP.Emerging fungal pathogens in immunocompromised patients:classification,diagnosis,and management.Clin Infect Dis,1993,17(Suppl 2):S487-S491. [2] Edmond MB,Wallace SE,McClish DK,et al.Nosocomial bloodstream infections in United States hospitals:a three-year analysis.Clin Infect Dis,1999,29(2):239-244. [3] Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30(4):696-709. [4] Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med,2002,347(6):408-415. [5] Walsh TJ,Teppler H,Donowitz GR,et al.Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med,2004,351(14):1391-1402. [6] Chen J,Li H,Li R,et al.Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.J Antimicrob Chemother,2005,55(1):31-37. [7] National Committee for Clinical Laboratory Standards.Reference method for broth dilution antifungal susceptibility testing of filamentous fungi.Approved standard M38-A.National Committee for Clinical Laboratory Standards,Wayne,Pa.2002. [8] Kurtz MB,Heath IB,Marrinan J,et al.Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against(1,3)-beta-D-glucan synthase.Antimicrob Agents Chemother,1994,38(7):1480-1489. [9] Jarvis B,Figgitt DP,Scott LJ.Micafungin.Drugs,2004,64(9):969-982. [10] Howard SJ,Webster I,Moore CB,et al.Multi-azole resistance in Aspergillus fumigatus.Int J Antimicrob Agents,2006,28(5):450-453. [11] Pfaller MA,Diekema DJ,Rex JH,et al.Correlation of MIC with outcome for Candida species tested against voriconazole:analysis and proposal for interpretive breakpoints.J Clin Microbiol,2006,44(3):819-826. |